Education, Science, Technology, Innovation and Life
Open Access
Sign In

Lynch Syndrome-Associated Colorectal Cancer with Tumor Disappearing after Toripalimab Injection Treatment: A Case Report

Download as PDF

DOI: 10.23977/medsc.2023.040701 | Downloads: 9 | Views: 360

Author(s)

Lu Lyu 1, Yali Yan 2, Guofang Gao 3

Affiliation(s)

1 Department of Allergy, Hohhot First Hospital, Hohhot, 010030, China
2 Department of Allergy and General Surgery, Hohhot First Hospital, Foundational and Translational Medical Reseach Center, Hohhot, 010030, China
3 Department of Pediatric Outpatient, Beijing Jishuitan Hospital, National Center for Orthopaedics, Beijing, 102208, China

Corresponding Author

Guofang Gao

ABSTRACT

This study aims to investigate the effect of immune checkpoint inhibitors in Lynch syndrome-associated colorectal cancer patients and provide a reference for treatment. A retrospective analysis of a case with multiple recurrences in colorectal cancer. The immune-related adverse effects and effect of Toripalimab Injection treatment is a case series study with a 2-year follow-up. The patient showed stable disease with immunotherapy for ten months. The tumor disappeared along with the download trend of blood tumor marker measurement. The immune-related adverse events were in remission during the treatment and eventually disappeared upon discontinuation of the medication. We believe our report can provide some references for treating this case and treating immune-related adverse reactions.

KEYWORDS

Lynch syndrome; Colorectal cancer; Immune checkpoint inhibitor; Immune-related adverse events

CITE THIS PAPER

Lu Lyu, Yali Yan, Guofang Gao, Lynch Syndrome-Associated Colorectal Cancer with Tumor Disappearing after Toripalimab Injection Treatment: A Case Report. MEDS Clinical Medicine (2023) Vol. 4: 1-5. DOI: http://dx.doi.org/10.23977/medsc.2023.040701.

REFERENCES

[1] Bhattacharya P, McHugh TW. Lynch Syndrome [J]. Treasure Island (FL): StatPearls Publishing, 2023. PMID: 28613748. 
[2] Rebuzzi F, Ulivi P, Tedaldi G. Genetic Predisposition to Colorectal Cancer: How Many and Which Genes to Test? [J]. Int J Mol Sci. 2023, 24(3):2137. Doi: 10. 3390/ijms24032137. PMID: 36768460; PMCID: PMC9916931. 
[3] Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, Li X. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022 Jul 16; 15(1):95. doi: 10. 1186/s13045-022-01294-4. PMID: 35842707; PMCID: PMC9288068. 
[4] Ofshteyn, A., Jiang, B., Bingmer, K., Nakayama, J. M, Gallego, C., Giglia, M., Stein, S. L, & Steinhagen, E. (2020). Prophylactic Gynecologic Surgery at Time of Colectomy Benefits Women with Lynch Syndrome and Colon Cancer: A Markov Cost-Effectiveness Analysis. Diseases of the colon and rectum, 63(10), 1393-1402. https://doi. org/10. 1097/DCR. 0000000000001681
[5] Shui L, Cheng K, Li X, Shui P, Zhou X, Li J, Yi C, Cao D. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. BMC Cancer. 2020 Jul 9; 20(1):636. doi: 10. 1186/s12885-020-07126-3. PMID: 32646394; PMCID: PMC7346390. 
[6] Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020 Mar;70(2):86-104. doi: 10. 3322/caac. 21596. Epub 2020 Jan 16. PMID: 31944278. 
[7] Shah NJ, Lacouture ME. Dermatologic immune-related adverse events to checkpoint inhibitors in cancer [J]. J Allergy Clin Immunol, 2023, 151(2):407-409. doi: 10. 1016/j. jaci. 2022. 11. 015. Epub 2022 Dec 2. PMID: 36463979. 
[8] Møller P, Seppälä T, Dowty JG, et al. Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium [J]. Hered Cancer Clin Pract, 2022, 20(1):36. doi: 10. 1186/s13053-022-00241-1. PMID: 36182917; PMCID: PMC9526951. 
[9] Desai S, Guddati AK. Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers. World J Oncol. 2023 Feb;14(1):4-14. doi: 10. 14740/wjon1425. Epub 2023 Feb 26. PMID: 36895994; PMCID: PMC9990734.

Downloads: 4553
Visits: 196981

Sponsors, Associates, and Links


All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.